Pennington, NJ, United States of America

Martin Eisman


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Martin Eisman: Innovator in Peripheral Atherosclerotic Disease Treatment

Introduction

Martin Eisman is a notable inventor based in Pennington, NJ (US). He has made significant contributions to the field of medicine, particularly in the treatment of peripheral atherosclerotic disease. His innovative approach has the potential to improve the quality of life for many patients suffering from this condition.

Latest Patents

Eisman holds a patent for a method aimed at treating peripheral atherosclerotic disease, specifically arteriosclerosis obliterans and intermittent claudication. The patent outlines a method that employs a cholesterol-lowering drug, such as an HMG CoA reductase inhibitor, either alone or in combination with an ACE inhibitor. This innovative treatment approach may include additional pharmaceutical options that reduce serum cholesterol through mechanisms other than inhibiting the production of specific enzymes.

Career Highlights

Martin Eisman is associated with E.R. Squibb & Sons, Inc., where he has been able to apply his expertise in developing effective treatments for cardiovascular diseases. His work has been instrumental in advancing medical therapies that address critical health issues.

Collaborations

Eisman collaborates with Mark E. McGovern, contributing to the development of innovative solutions in the medical field. Their partnership exemplifies the importance of teamwork in driving advancements in healthcare.

Conclusion

Martin Eisman's contributions to the treatment of peripheral atherosclerotic disease highlight his role as an innovator in the medical field. His patent and collaborative efforts reflect a commitment to improving patient outcomes through innovative therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…